Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72690
Title:
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.
Authors:
Horsman, Michael R; Bohm, Lothar; Margison, Geoffrey P; Milas, Luka; Rosier, Jean-Francois; Safrany, Geza; Selzer, Edgar; Verheij, Marcel; Hendry, Jolyon H
Abstract:
PURPOSE: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. RESULTS: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. CONCLUSION: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.
Affiliation:
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.
Citation:
Tumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. 2006, 64 (2):551-61 Int. J. Radiat. Oncol. Biol. Phys.
Journal:
International Journal of Radiation Oncology, Biology, Physics
Issue Date:
1-Feb-2006
URI:
http://hdl.handle.net/10541/72690
DOI:
10.1016/j.ijrobp.2005.09.032
PubMed ID:
16414371
Type:
Article
Language:
en
ISSN:
0360-3016
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorHorsman, Michael R-
dc.contributor.authorBohm, Lothar-
dc.contributor.authorMargison, Geoffrey P-
dc.contributor.authorMilas, Luka-
dc.contributor.authorRosier, Jean-Francois-
dc.contributor.authorSafrany, Geza-
dc.contributor.authorSelzer, Edgar-
dc.contributor.authorVerheij, Marcel-
dc.contributor.authorHendry, Jolyon H-
dc.date.accessioned2009-07-07T10:58:56Z-
dc.date.available2009-07-07T10:58:56Z-
dc.date.issued2006-02-01-
dc.identifier.citationTumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting. 2006, 64 (2):551-61 Int. J. Radiat. Oncol. Biol. Phys.en
dc.identifier.issn0360-3016-
dc.identifier.pmid16414371-
dc.identifier.doi10.1016/j.ijrobp.2005.09.032-
dc.identifier.urihttp://hdl.handle.net/10541/72690-
dc.description.abstractPURPOSE: The International Atomic Energy Agency (IAEA) held a Technical Meeting of Consultants to (1) discuss a selection of relatively new agents, not those well-established in clinical practice, that operated through a variety of mechanisms to sensitize tumors to radiation and (2) to compare and contrast their tumor efficacy, normal tissue toxicity, and status of development regarding clinical application. The aim was to advise the IAEA as to which developing agent or class of agents would be worth promoting further, by supporting additional laboratory research or clinical trials, with the eventual goal of improving cancer control rates using radiotherapy, in developing countries in particular. RESULTS: The agents under discussion included a wide, but not complete, range of different types of drugs, and antibodies that interfered with molecules in cell signaling pathways. These were contrasted with new molecular antisense and gene therapy strategies. All the drugs discussed have previously been shown to act as tumor cell radiosensitizers or to kill hypoxic cells present in tumors. CONCLUSION: Specific recommendations were made for more preclinical studies with certain of the agents and for clinical trials that would be suitable for industrialized countries, as well as trials that were considered more appropriate for developing countries.en
dc.language.isoenen
dc.subjectCanceren
dc.subject.meshAngiogenesis Inhibitors-
dc.subject.meshApoptosis-
dc.subject.meshCell Hypoxia-
dc.subject.meshCyclooxygenase 2 Inhibitors-
dc.subject.meshGene Therapy-
dc.subject.meshInternational Agencies-
dc.subject.meshNeoplasms-
dc.subject.meshOligoribonucleotides, Antisense-
dc.subject.meshRadiation-Sensitizing Agents-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.titleTumor radiosensitizers--current status of development of various approaches: report of an International Atomic Energy Agency meeting.en
dc.typeArticleen
dc.contributor.departmentDepartment of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark.en
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.